title: Thrombectomy reduces the systemic complications in device-related right atrial septic thrombosis.
abstract: BACKGROUND
  Septic thrombosis of the right atrium is an unusual complication associated with the use of indwelling devices. The optimal management of this condition is unclear. Our experience with a patient with hemodialysis catheter-related septic thrombosis of the right atrium illustrates the difficulties associated with this condition.
  
  
  OBJECTIVE
  To determine the effects of surgical thrombectomy compared with nonsurgical treatment with antibiotics (with or without anticoagulation) on mortality rates and complications in patients with device-related septic thrombosis of the right atrium.
  
  
  METHODS
  A retrospective analysis of all reported cases of device-related right heart septic thrombosis in which therapy and outcome were reported was conducted using a PubMed search in the English-language literature (1985 to 2006).
  
  
  RESULTS
  Forty cases of device-related right atrial septic thromboses were reported in the literature during the chosen time period. The treatments administered were none (12.5%), antibiotics (12.5%), antibiotics and anticoagulation (20%), and thrombectomy (55%). The mean clot size was significantly larger in patients who underwent thrombectomy. All untreated patients died. Excluding the untreated patients from the analysis, systemic complications were significantly lower in the thrombectomy group than in the groups receiving nonsurgical therapies. Using multivariate modelling with survival as the primary outcome, age, sex, clot size, clot location, microbial organism or type of treatment were not predictive of the outcome.
  
  
  CONCLUSIONS
  Device-related right atrial septic thrombosis is associated with significant mortality and is uniformly fatal if untreated. Surgical thrombectomy is associated with less frequent systemic complications. A well-designed prospective, randomized trial is needed to determine the optimal treatment of this condition.
authors.affiliation: Division of Cardiology, Creighton University, Omaha, Nebraska 68131, USA. ssontineni@gmail.com
authors.forename: Siva Prasad
authors.initials: SP
authors.lastname: Sontineni
authors.forename: Michael
authors.initials: M
authors.lastname: White
authors.forename: Sindhu
authors.initials: S
authors.lastname: Singh
authors.forename: Amy
authors.initials: A
authors.lastname: Arouni
authors.forename: David
authors.initials: D
authors.lastname: Cloutier
authors.forename: Chandra K
authors.initials: CK
authors.lastname: Nair
authors.forename: Syed M
authors.initials: SM
authors.lastname: Mohiuddin
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D002408:Catheters, Indwelling / Q000009:adverse effects*; D006325:Heart Atria / Q000382:microbiology*; D006331:Heart Diseases / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D006435:Renal Dialysis / Q000295:instrumentation; D012189:Retrospective Studies; D018805:Sepsis / Q000150:complications / Q000517:prevention & control / Q000601:surgery*; D016019:Survival Analysis; D017131:Thrombectomy; D013927:Thrombosis / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000925:Anticoagulants